Purpose To evaluate real world efficacy and safety of the Preserflo MicroShunt (PM) in a heterogenous patient cohort at a single tertiary eye care centre. Patients and methods A retrospective data analysis of PM implantations between 2019 and 2022 was performed. Primary outcome measures were complete-, qualified-, and overall- success as well as failure defined according to the WGA criteria. Secondary outcomes were intraocular pressure (IOP) and IOP lowering medications. Result 38 patients were included in the study. After 24 months, complete success was achieved in 31.58% and qualified success in 28.95% whereas 39.47% were classified as failure. IOP was reduced by 55.2% from mean 25.57 ± 10.03 mmHg at baseline to 11.45 ± 3.37 mmHg two years postoperative in eyes classified as success. The number of IOP lowering medications was reduced from 2.73 ± 1.33 before surgery to 1.14 ± 1.31 at the end of the follow-up period. Conclusion Two years postoperatively an overall success rate of 60.53% was achieved and a significant IOP reduction was preserved over the complete two years follow-up time. Key Messages <Emphasis Type="BoldItalic">What is known</Emphasis><UnorderedList Mark="Bullet"> <ItemContent> Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure. </ItemContent> <ItemContent> The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. </ItemContent> </UnorderedList> <Emphasis Type="BoldItalic">What is new</Emphasis><UnorderedList Mark="Bullet"> <ItemContent> Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up. </ItemContent> <ItemContent> An overall surgical success rate of 60.53% was achieved. </ItemContent> <ItemContent> An intraocular pressure reduction of 50.2% was sustained over the two years follow up period. </ItemContent> </UnorderedList>

Surgical success 2 years after preserflo microshunt implantation: real world data from a single eye care centre

期刊论文
发表日期：

2025年2月12日

查看全文

Sarah Hinterberger,
Sophie Schneider,
Martin Kallab,
Olivia Murauer,
Anna-Sophie Reisinger,
Matthias Bolz,
Clemens A. Strohmaier

摘要

Purpose

To evaluate real world efficacy and safety of the Preserflo MicroShunt (PM) in a heterogenous patient cohort at a single tertiary eye care centre.

Patients and methods

A retrospective data analysis of PM implantations between 2019 and 2022 was performed. Primary outcome measures were complete-, qualified-, and overall- success as well as failure defined according to the WGA criteria. Secondary outcomes were intraocular pressure (IOP) and IOP lowering medications.

Result

38 patients were included in the study. After 24 months, complete success was achieved in 31.58% and qualified success in 28.95% whereas 39.47% were classified as failure. IOP was reduced by 55.2% from mean 25.57 ± 10.03 mmHg at baseline to 11.45 ± 3.37 mmHg two years postoperative in eyes classified as success. The number of IOP lowering medications was reduced from 2.73 ± 1.33 before surgery to 1.14 ± 1.31 at the end of the follow-up period.

Conclusion

Two years postoperatively an overall success rate of 60.53% was achieved and a significant IOP reduction was preserved over the complete two years follow-up time.

Key Messages

What is known

Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.

The success rates reported for primary open angle glaucoma are comparable to trabeculectomy.

What is new

Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.

An overall surgical success rate of 60.53% was achieved.

An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.